与坎德沙坦相比,阿齐尔沙坦对左心室透静功能障碍的疗效:J-TASTE随机对照试验
Shin Ito1,2, Hiroyuki Takahama1,3, Masanori Asakura2,4
1Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
Scientific reports
|August 2, 2023
概括
与坎德沙坦相比,阿齐尔沙坦在心力衰竭的高血压患者中没有显著改善左心室静脉功能. 需要进一步的研究来证实阿齐尔沙坦的存在.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭与由于心室和血管硬而导致的高发病率和死亡率有关.
- 阿齐尔沙坦是一种血管激素受体阻断剂,具有很高的心肌和血管亲和力,这表明它对扩张功能有潜在的益处.
研究的目的:
- 为了比较阿齐尔沙坦与坎德沙坦在改善左心室 (LV) 扩张功能方面的疗效,在高血压患者中,阿齐尔沙坦和坎德沙坦在改善左心室 (LV) 扩张功能,在高血压患者中,阿齐尔沙坦和坎德沙坦在改善左心室 (LV) 扩张功能,在高血压患者中,阿齐尔沙坦和坎德沙坦在改善左心室 (LV) 扩张功能.
主要方法:
- 一个随机的,开放的试验,涉及193名高血压患者,HF和LV射出分数≥45%.
- 患者被分配每天接受阿齐尔沙坦 (20毫克) 或坎德沙坦 (8毫克) 治疗,持续48周.
- 主要终点是早期透过性心经传导流速 (E) 与早期透过性心经环状流速 (e') (E/e') 的比率的变化.
主要成果:
- 经调整的E/e'中小方位平均变化为-0.8对于阿齐尔沙坦和-0.2对于坎德沙坦,非显著差异为-1.0 (P=0.057).
- 左心房体积指数的中位变化为阿齐尔沙坦的-2.7mL/m2与坎德沙坦的1.4mL/m2 (P=0.091).
- 与低血压和高血相关的不良事件在各组之间相似.
结论:
- 这项研究没有提供强有力的证据表明,阿齐尔沙坦在目标患者群体中改善了LV静脉动态功能障碍.
- 需要进一步的证实性研究来确定阿齐尔沙坦在管理HFpEF和HFmrEF中的作用.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
3.6K
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
4.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:25Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780